ZIVO Pengajuan SEC - ZIVO Bioscience, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300WXWSRBQ5NTCF69
CIK	1101026

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ZIVO Bioscience, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission Fil
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40449 Zivo Bio
July 14, 2025	EX-10.1	Form of Bridge Promissory Note EXHIBIT 10.1 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SEC
July 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File N
July 14, 2025	EX-4.1	Form of Common Stock Purchase Warrant EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File N
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40449 Zivo Bi
April 25, 2025	DEFA14A	UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIESAND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definiti
April 25, 2025	ARS	ARS
April 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
March 18, 2025	EX-19	Insider Trading Policy EXHIBIT 19 INSIDER TRADING COMPLIANCE POLICY This Insider Trading Compliance Policy (this “Policy”) consists of four sections: Section I provides an overview; Section II sets forth the policies of ZIVO BIOSCIENCE, INC.
March 18, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30415 ZIVO BIOSCIENCE, INC.
March 18, 2025	EX-21.1	Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries of the Registrant Zivo Bioscience, Inc. has the following Subsidiaries: Jurisdiction of Incorporation or Organization Health Enhancement Corporation Nevada Corporation HEPI Pharmaceuticals, Inc. Nevada Corporation Wellmetrix, LLC Delaware limited liability company Wellmetris, LLC Delaware limited liability company Zivo Biologic, Inc. Delaware corporation Zivo Bioscience,
January 27, 2025	8-K	Unregistered Sales of Equity Securities FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2025 ZIVO BIOSCIENCE, INC.
January 15, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission Fil
January 15, 2025	EX-10.1	Form of Exchange Agreement EXHIBIT 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of latest signature date below (the “Effective Date”) by and among investor name (the “Investor”) on the one hand and Zivo Bioscience, Inc., a Nevada corporation (the “Company”) on the other. Whereas, the Company and the Investor are party to a License Co-Development Participation Agreement dated [origina
January 7, 2025	8-K	Other Events FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 ZIVO BIOSCIENCE, INC.
January 7, 2025	EX-1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, Strome Investment Management, LP, Strome Group, Inc.
November 15, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission F
November 15, 2024	EX-10.1	Debt Settlement Agreement, dated November 12, 2024, by and between Howard Shapiro and the Company EXHIBIT 10.1
November 14, 2024	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40449 Ziv
October 18, 2024	8-K	Unregistered Sales of Equity Securities FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 ZIVO BIOSCIENCE, INC.
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40449 Zivo Bio
July 17, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
June 13, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
June 12, 2024	SC 13D	ZIVO / ZIVO Bioscience, Inc. / Cornell Alison A - FORM SC 13D Activist Investment SC 13D 1 zivosc13d.htm FORM SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Zivo Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 98978N 3098 (CUSIP Number) Alison A. Cornell C/O Zivo Bioscience, Inc. 21 East Long Lake Road, Suite 100 Bloomfield Hil
June 12, 2024	SC 13D	ZIVO / ZIVO Bioscience, Inc. / Marchiando Keith - SC 13D Activist Investment SC 13D 1 zivosc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Zivo Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 98978N 3098 (CUSIP Number) Keith Marchiando C/O Zivo Bioscience, Inc. 21 East Long Lake Road, Suite 100 Bloomfield Hills, MI
June 12, 2024	SC 13D	ZIVO / ZIVO Bioscience, Inc. / PAYNE JOHN BERNARD - SC 13D Activist Investment SC 13D 1 zivosc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Zivo Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 98978N 3098 (CUSIP Number) John Bernard Payne C/O Zivo Bioscience, Inc. 21 East Long Lake Road, Suite 100 Bloomfield Hills,
June 7, 2024	8-K/A	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 (May 31, 2024) ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (
June 7, 2024	SC 13D/A	ZIVO / ZIVO Bioscience, Inc. / Maggiore Christopher D. - FORM SC 13D/A Activist Investment SC 13D/A 1 zivosc13da.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Zivo Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Christopher D. Maggiore 4788 Nobles Pond Dr. NW Canton, OH 44718 248-452-9866 Name, Add
June 6, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File N
June 6, 2024	EX-10.2	Amended Non-Employee Director Compensation Policy EXHIBIT 10.2
June 6, 2024	EX-10.1	2024 Equity Incentive Plan for Non-Employee Directors and Form Grant Agreements EXIHIBIT 10.1
June 6, 2024	EX-10.3	First Amendment to 2021 Equity Incentive Plan EXHIBIT 10.3 FIRST AMENDMENT TO ZIVO BIOSCIENCE, INC, 2021 EQUITY INCENTIVE PLAN This First Amendment is adopted effective as of the 31st day of May, 2024 by Zivo Bioscience, Inc. (the “Company”). WHEREAS, the Company has adopted the Zivo Bioscience, Inc. 2021 Equity Incentive Plan (as amended, restated, supplemented or otherwise modified from time to time, the “Plan”); WHEREAS, the Plan initially
May 31, 2024	CORRESP	May 31, 2024 May 31, 2024 VIA EDGAR TRANSMISSION Division of Corporation Finance Office of Technology U.
May 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40449 Zivo Bi
April 26, 2024	ARS	ARS - PDF COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30415 ZIVO BIOSCIENCE, INC.
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
April 26, 2024	ARS	ARS
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 9, 2024	SC 13D/A	ZIVO / ZIVO Bioscience, Inc. / STROME MEZZANINE FUND, LP - AMENDMENT NO. 7 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $.001 par value (Title of Class of Securities) 98978N 3098 (CUSIP Number) Timothy R. Damschroder Bodman PLC 201 S. Division, Suite 400 Ann Arbor, MI 48104 (Name, Address and Telephone Number of Perso
March 15, 2024	EX-21.1	Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries of the Registrant Zivo Bioscience, Inc. has the following Subsidiaries: Jurisdiction of Incorporation or Organization Health Enhancement Corporation Nevada Corporation HEPI Pharmaceuticals, Inc. Nevada Corporation Wellmetrix, LLC Delaware limited liability company Wellmetris, LLC Delaware limited liability company Zivo Biologic, Inc. Delaware corporation Zivo Bioscience,
March 15, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30415 ZIVO BIOSCIENCE, INC.
February 15, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission F
January 22, 2024	SC 13D	ZIVO / ZIVO Bioscience, Inc. / Maggiore Christopher D. - SC 13D Activist Investment SC 13D 1 zivosc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Zivo Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Christopher D. Maggiore 4788 Nobles Pond Dr. NW Canton, OH 44718 Name, Address and Telephone Numb
January 17, 2024	8-K	FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 ZIVO BIOSCIENCE, INC.
January 5, 2024	8-K	Unregistered Sales of Equity Securities FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 ZIVO BIOSCIENCE, INC.
January 3, 2024	8-K	FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 ZIVO BIOSCIENCE, INC.
December 11, 2023	8-K	Unregistered Sales of Equity Securities FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 ZIVO BIOSCIENCE, INC.
December 1, 2023	RW	Zivo Bioscience, Inc. 21 East Long Lake Road, Suite 100, Bloomfield Hills, Michigan 48304 Zivo Bioscience, Inc. 21 East Long Lake Road, Suite 100, Bloomfield Hills, Michigan 48304 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 United States of America Attention: Mr. Daniel Crawford RE: Zivo Bioscience, Inc. Request to Withdraw Registration Statement on Form S-1 (File No. 333-274867) Dear Mr. Crawford: Pursuant
November 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission F
November 22, 2023	EX-10.1	Subscription Agreement EXHIBIT 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made as of November 16, 2023, by and among Zivo Bioscience, Inc., a Nevada corporation (the “Company”), and HEP Investments, LLC (the “Subscriber”). RECITALS Whereas, the Company seeks to sell a maximum of $150,000 (or such higher amount as the Company’s Board of Directors shall determine) (the “Total Amount”) in
November 22, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission F
November 22, 2023	EX-4.1	ZIVO BIOSCIENCE, INC. PROMISSORY NOTE EXHIBIT 4.1 THIS PROMISSORY NOTE MAY BE SOLD ONLY IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS. THIS SUBORDINATED NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS OR ANY OTHER APPLICABLE SECURITIES LAWS. NEITHER THIS PROMISSORY NOTE NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED,
November 13, 2023	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40449 Zivo
November 3, 2023	S-1/A	As filed with the Securities and Exchange Commission on November 3, 2023 As filed with the Securities and Exchange Commission on November 3, 2023 Registration No.
November 1, 2023	S-1/A	As filed with the Securities and Exchange Commission on October 31, 2023 As filed with the Securities and Exchange Commission on October 31, 2023 Registration No.
November 1, 2023	EX-4.4	Form of Common Stock Purchase Warrant EXHIBIT 4.4 WARRANT TO PURCHASE SHARES OF COMMON STOCK ZIVO BIOSCIENCE, INC. Warrant Shares: Initial Exercise Date: THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof
November 1, 2023	EX-10.11	Form of Securities Purchase Agreement EXHIBIT 10.11 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [*], 2023, between Zivo Bioscience, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for
November 1, 2023	EX-10.12	Form of Lock-Up Agreement EXHIBIT 10.12 LOCK-UP AGREEMENT [], 2023 Zivo Bioscience, Inc. 21 E. Long Lake Road, Suite 100 Bloomfield Hills, MI 48304 Re: Securities Purchase Agreement, dated as of [], 2023 (the “Purchase Agreement”), between Zivo Bioscience, Inc. (the “Company”) and the purchasers signatory thereto Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) s
November 1, 2023	EX-10.13	Form of Placement Agency Agreement EXHIBIT 10.13 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 [*], 2023 Zivo Bioscience, Inc. 21 E. Long Lake Road, Suite 100 Bloomfield Hills, MI 48304 Attention: John B. Payne Re: Placement Agency Agreement Dear Mr. Payne: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement
November 1, 2023	EX-4.5	Form of Pre-Funded Warrant EXHIBIT 4.5 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK ZIVO BIOSCIENCE, INC. Warrant Shares: Initial Exercise Date: THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
October 30, 2023	EX-99.8	Debt Extension and Conversion Agreement, dated March 3, 2021, by and among Strome Mezzanine Fund, LP, Strome Alpha Fund, LP and HEP Investments, LLC. EX-99.8 2 ea187380ex99-8zivobio.htm DEBT EXTENSION AND CONVERSION AGREEMENT, DATED MARCH 3, 2021, BY AND AMONG STROME MEZZANINE FUND, LP, STROME ALPHA FUND, LP AND HEP INVESTMENTS, LLC Exhibit 8 DEBT EXTENSION AND CONVERSION AGREEMENT THIS DEBT EXTENSION AND CONVERSION AGREEMENT (this “Agreement”) is dated as of March 3, 2021 by and between Strome Mezzanine Fund LP and Strome Alpha Fund LP (the “P
October 30, 2023	SC 13D/A	ZIVO / Zivo Bioscience Inc / STROME MEZZANINE FUND, LP - AMENDMENT NO. 6 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Timothy R. Damschroder Bodman PLC 201 S. Division, Suite 400 Ann Arbor, MI 48104 (Name, Address and Telephone Number of Person
October 26, 2023	EX-3.1	Certificate of Amendment dated October 25, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q filed on October 26, 2023) EXHIBIT 3.1
October 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 Zivo Bioscience, Inc. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 26, 2023	EX-99.1	ZIVO Bioscience Announces Reverse Stock Split EXHIBIT 99.1 ZIVO Bioscience Announces Reverse Stock Split BLOOMFIELD HILLS, Mich., October 26, 2023 -(BUSINESS WIRE)- Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that the Board of Directors of the Company approved a 1-for-6 reverse
October 4, 2023	EX-FILING FEES	Filing Fee Table (previously filed as Exhibit 107 to the Registrant’s Registration Statement on Form S-1, filed on October 4, 2023) EXHIBIT 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Zivo Bioscience, Inc.
October 4, 2023	S-1	As filed with the Securities and Exchange Commission on October 4, 2023 As filed with the Securities and Exchange Commission on October 4, 2023 Registration No.
August 14, 2023	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40449 Zivo Biosc
August 9, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
August 3, 2023	424B3	2,996,260 shares of Common Stock underlying Series A Common Warrants and Series B Common Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-273493 PROSPECTUS 2,996,260 shares of Common Stock underlying Series A Common Warrants and Series B Common Warrants This prospectus relates to the resale from time to time by the selling stockholder identified in this prospectus under the caption “Selling Stockholder” (the “selling stockholder”) of up to an aggregate of 2,996,260 shares of comm
August 1, 2023	CORRESP	August 1, 2023 August 1, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Jimmy McNamara Re: Zivo Bioscience, Inc. Registration Statement on Form S-3 File No. 333-273493 Acceleration Request Requested Date: August 3, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities
July 28, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Zivo Bioscience, Inc.
July 28, 2023	S-3	As filed with the Securities and Exchange Commission on July 27, 2023 As filed with the Securities and Exchange Commission on July 27, 2023 Registration No.
July 6, 2023	EX-4.2	Form of Series B Common Warrant (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on July 6, 2023) EXHIBIT 4.2 EXECUTION VERSION NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
July 6, 2023	EX-10.1	Form of Securities Purchase Agreement, dated June 20, 2023 (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on July 6, 2023) EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 30, 2023, between Zivo Bioscience, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set
July 6, 2023	8-K	FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 ZIVO BIOSCIENCE, INC.
July 6, 2023	EX-99.1	ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market EXHIBIT 99.1 ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market BLOOMFIELD HILLS, Mich., June 30, 2023 -(BUSINESS WIRE)- Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it has entered
July 6, 2023	EX-1.1	Form of Placement Agent Agreement. EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT June 30, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Zivo Bioscience, Inc., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of approximately $4 million of registered securities of the Company, including, but
July 6, 2023	EX-4.1	Form of Series A Common Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on July 6, 2023) EXHIBIT 4.1 EXECUTION VERSION NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
July 6, 2023	EX-4.3	Form of Pre-Funded Warrant (previously filed as Exhibit 4.3 to the Registrant’s Current Report on Form 8-K, filed on July 6, 2023) EXHIBIT 4.3 EXECUTION VERSION PRE-FUNDED COMMON STOCK PURCHASE WARRANT ZIVO BIOSCIENCE, INC. Warrant Shares: 468,130 CUSIP: 98978N 200 ISIN: US98978N2009 Initial Exercise Date: July 5, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this "Warrant") certifies that, for value received, Armistice Capital Master Fund Ltd., or its assigns (the “Holder”), is entitled, upon the terms and subject to t
July 5, 2023	424B5	1,030,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 468,130 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-259082 PROSPECTUS SUPPLEMENT (To the Prospectus dated August 26, 2021) 1,030,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 468,130 Shares of Common Stock We are offering directly to a single institutional investor 1,030,000 shares of our common stock, par value $0.001 per share (“Common Stock”), and pre-funded warrants to pur
June 28, 2023	RW	Zivo Bioscience, Inc. 21 East Long Lake Road, Suite 100, Bloomfield Hills, Michigan 48304 Zivo Bioscience, Inc. 21 East Long Lake Road, Suite 100, Bloomfield Hills, Michigan 48304 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 United States of America Attention: Mr. Arzhang Navai RE: Zivo Bioscience, Inc. Request to Withdraw Registration Statement on Form S-1 (File No. 333-270750) Dear Mr. Navai: Pursuant to R
June 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
May 26, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 ZIVO BIOSCIENCE, INC.
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40449 Zivo Bi
April 28, 2023	ARS	ARS 81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21 :DVKLQJWRQ'& )RUP.
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
April 28, 2023	ARS	ARS
April 5, 2023	EX-10.1	Subscription Agreement (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on April 5, 2023) EXHIBIT 10.1 Certain identified information has been excluded from the exhibit because it is both not material and is of the type that the Company treats as private or confidential. Double asterisks denote omissions. SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of April 3, 2023, by and among ZIVO BIOSCIENCE, INC., a Nevada corporation (the “Company”), and John B
April 5, 2023	EX-99.1	ZIVO Bioscience Receives $1 Million Bridge Financing EXHIBIT 99.1 ZIVO Bioscience Receives $1 Million Bridge Financing BLOOMFIELD HILLS, Mich. (April 5, 2023) – Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced a $1 million unsecured six-month loan from its Chairman, Chief E
April 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
April 5, 2023	EX-4.2	Warrant (incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on April 5, 2023) EXHIBIT 4.2 NEITHER THIS WARANT NOR THE SHARES OF STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR STATE SECURITIES LAWS. NO SALE, TRANSFER OR OTHER DISPOSITION OF THIS WARRANT OR SAID SHARES MAY BE EFFECTED WITHOUT (i) AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS, OR (ii) AN EXEMPTIO
April 5, 2023	EX-4.1	Note (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed on April 5, 2023) EXHIBIT 4.1 THIS PROMISSORY NOTE MAY BE SOLD ONLY IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS. THIS SUBORDINATED NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS OR ANY OTHER APPLICABLE SECURITIES LAWS. NEITHER THIS PROMISSORY NOTE NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED,
March 22, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Zivo Bioscience, Inc.
March 22, 2023	EX-10.4	Amendment No. 1 to Employment Agreement, dated as of December 16, 2022, by and between John Payne and the Company (previously filed as Exhibit 10.4.1 to the Registrants Registration Statement on Form S-1 filed on March 22, 2023) EXHIBIT 10.4.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of December 22, 2022 (the “Effective Date”), by and between John Payne (“Executive”) and Zivo Bioscience, Inc., a Nevada corporation (the “Company”). Executive and the Company are referred to herein each as a “Party” and, together, as the “Parties.” Cap
March 22, 2023	EX-10.11	Form of Placement Agency Agreement EXHIBIT 10.11 PLACEMENT AGENCY AGREEMENT March [●], 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Zivo Bioscience, Inc., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $15 million of registered securities of the Company, including, but not limi
March 22, 2023	EX-4.1	Form of Common Stock Purchase Warrant EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT ZIVO BIOSCIENCE, INC. Warrant Shares: [●] CUSIP: 98978N 101 ISIN: [●] Issue Date: [●], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, , or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue
March 22, 2023	EX-4.3	Form of Pre-Funded Warrant EXHIBIT 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ZIVO BIOSCIENCE, INC. Warrant Shares: [●] CUSIP: 98978N 101 ISIN: [●] Initial Exercise Date: [●], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, , or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth,
March 22, 2023	EX-4.2	Form of Warrant Agency Agreement EXHIBIT 4.2 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of [], 2023 (the “Issuance Date”) between ZIVO Bioscience, Inc., a company incorporated under the laws of the State of Nevada (the “Company”), and Direct Transfer LLC, a Delaware limited liability company (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Placement Agency Agreement (“
March 22, 2023	S-1	As filed with the Securities and Exchange Commission on March 22, 2023 As filed with the Securities and Exchange Commission on March 22, 2023 Registration No.
March 22, 2023	EX-10.10	Form of Securities Purchase Agreement EXHIBIT 10.10 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March [●], 2023, between Zivo Bioscience, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s
March 14, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30415 Zivo Bioscience, Inc.
March 14, 2023	EX-21.1	Subsidiaries of the Registrant (previously filed as Exhibit 21.1 to the Registrant Annual Report on Form 10-K on March 14, 2023) EXHIBIT 21.1 Subsidiaries of the Registrant Zivo Bioscience, Inc. has the following Subsidiaries: Jurisdiction of Incorporation or Organization Health Enhancement Corporation Nevada Corporation HEPI Pharmaceuticals, Inc. Nevada Corporation Wellmetrix, LLC Delaware limited liability company Wellmetris, LLC Delaware limited liability company Zivo Biologic, Inc. Delaware corporation Zivo Bioscience,
February 14, 2023	SC 13D/A	ZIVO / Zivo Bioscience Inc / Maggiore Christopher D. - SC 13D/A Activist Investment SC 13D/A 1 zivosc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Zivo Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Christopher D. Maggiore 4788 Nobles Pond Dr. NW Canton, OH 44718 Name, Address and Telephone
February 10, 2023	EX-99.1	2 EXHIBIT 99.1 2
February 10, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission F
November 29, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission F
November 14, 2022	10-Q	Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40449 Zivo Bioscience, In
August 23, 2022	EX-99.1	Corporate Updates August 2022 EXHIBIT 99.1 Corporate Updates August 2022 August 23, 2022 White Paper Submission to USDA In August 2022, Zivo Bioscience, Inc. (the ?Company?) announced receipt of a letter from the U.S. Department of Agriculture?s (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the Company?s novel immune-modulating biologic for treating coccidiosis in
August 23, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission Fil
August 4, 2022	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40449 Zivo Biosc
August 3, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
July 7, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
July 7, 2022	EX-3.1	Second Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on July 7, 2022) EXHIBIT 3.1 SECOND AMENDED AND RESTATED BYLAWS OF ZIVO BIOSCIENCE, INC. (A Nevada Corporation) ARTICLE I STOCKHOLDERS Section 1.1 Annual Meeting. The annual meeting of the stockholders of the corporation shall be held each year on such date as shall be fixed by the board of directors, at such time and place within or without the State of Nevada as may be designated in the notice of meeting. At the
July 5, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) DEF 14A 1 zivodef14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p
June 28, 2022	8-K	Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
June 22, 2022	S-8	As filed with the Securities and Exchange Commission on June 22, 2022 As filed with the Securities and Exchange Commission on June 22, 2022 Registration No.
June 22, 2022	EX-FILING FEES	Calculation of Filing Fee Table FORM S-8 (Form Type) Zivo Bioscience, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Zivo Bioscience, Inc.
May 20, 2022	EX-99.1	Corporate Updates May 2022 EXHIBIT 99.1 Corporate Updates May 2022 May 20, 2022 White Paper Submission to USDA In early May 2022, Zivo Bioscience, Inc. (the ?Company?) submitted a white paper titled ?A Novel Bacterially Derived Immune Modulator for Mitigation of the Effects of Coccidiosis in Poultry? to the United States Department of Agriculture (?USDA?). The white paper provides a comprehensive overview of the Company?s p
May 20, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File N
May 13, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40449 Zivo Bi
May 2, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A (Amendment No.
April 25, 2022	EX-99.1	Zivo Bioscience Regains Compliance Following Receipt of Noncompliance Notice from Nasdaq EXHIBIT 99.1 Zivo Bioscience Regains Compliance Following Receipt of Noncompliance Notice from Nasdaq BLOOMFIELD HILLS, Mich., (April 25, 2022) ? ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the ?Company?), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it received a Notice
April 25, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
April 22, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30415 Zivo Bioscience, Inc.
April 22, 2022	EX-10.8	Non-Employee Director Compensation Policy EXHIBIT 10.8 ZIVO BIOSCIENCE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Zivo Bioscience, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy for such Eligi
April 22, 2022	EX-4.2	Form of Warrant (incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K filed on April 22, 2022) EXHIBIT 4.2 NEITHER THIS WARRANT NOR THE SHARES OF STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR STATE SECURITIES LAWS. NO SALE, TRANSFER OR OTHER DISPOSITION OF THIS WARRANT OR SAID SHARES MAY BE EFFECTED (i) WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS, OR (ii) UNLESS THE
April 22, 2022	EX-4.1	Description of Securities EXHIBIT 4.1 DESCRIPTION OF THE SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the terms of our capital stock is qualified in its entirety by reference to our articles of incorporation, as amended (?Articles of Incorporation?) and amended and restated bylaws (?Bylaws?), copies of which are filed as exhibits to our Annual Report on Form 1
April 22, 2022	EX-21.1	Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries of the Registrant Zivo Bioscience, Inc. has the following Subsidiaries: Jurisdiction of Incorporation or Organization Health Enhancement Corporation Nevada Corporation HEPI Pharmaceuticals, Inc. Nevada Corporation Wellmetrix, LLC Delaware limited liability company Wellmetris, LLC Delaware limited liability company Zivo Biologic, Inc. Delaware corporation Zivo Bioscience,
April 21, 2022	10-Q/A	United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:
April 15, 2022	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission File
March 31, 2022	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-30415 CUSIP NUMBER 98978N200 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra
March 1, 2022	EX-17	Email from Andrew Dahl dated February 25, 2022 EXHIBIT 17 Please convey my sentiments to the board of directors regarding the 8-K as filed: You?ve allotted me only a few hours to review, and to consult with counsel regarding, your proposed version of the Form 8-K, waiting until the very last day to notice me.
March 1, 2022	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorpor
February 25, 2022	EX-17	Notice of Resignation EXHIBIT 17 1 2
February 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission F
February 16, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2022 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission F
February 16, 2022	EX-10.2	2021 Equity Incentive Plan (previously filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on February 16, 2022) EXHIBIT 10.2 ZIVO BIOSCIENCE, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: September 4, 2021 APPROVED BY THE STOCKHOLDERS: October 12, 2021 1. GENERAL. (a) Plan Purpose. The Company, by means of this Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Comp
February 16, 2022	EX-10.1	Employment Agreement, dated as of February 15, 2022, by and between John Payne and the Company (previously filed as Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed on February 16, 2022) EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of February 15, 2022 (the ?Effective Date?), by and between Zivo Bioscience, Inc., a Nevada corporation (the ?Company?), and John Payne (?Employee?). Recitals: A. The Company desires to employ Employee as its Chief Executive Officer and President and desires to enter into an agreement with Emp
January 11, 2022	EX-99.1	ZIVO Bioscience Names Chairman John B. Payne as President and CEO EXHIBIT 99.1 ZIVO Bioscience Names Chairman John B. Payne as President and CEO KEEGO HARBOR, Mich., (January 10, 2022) ? ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (?ZIVO? or the ?Company?), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that Chairman of the Boar
January 11, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 (January 4, 2022) ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporati
December 10, 2021	EX-16.1	Letter of Wolinetz, Lafazan & Company, P.C. dated December 9, 2021 EXHIBIT 16.1 December 9, 2021 U.S. Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 RE: Zivo Bioscience, Inc. Ladies and Gentlemen: We have read the statements of Zivo Bioscience, Inc. pertaining to our Firm included under Item 4.01 of Form 8-K/A dated December 9, 2021 and agree with such statements as they pertain to our Firm. We have no basis to agree or disagree with ot
December 10, 2021	8-K/A	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission
December 9, 2021	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission F
December 9, 2021	EX-16.1	Letter of Wolinetz, Lafazan & Company, P.C. dated December 8, 2021 EXHIBIT 16.1 December 8, 2021 U.S. Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 RE: Zivo Bioscience, Inc. Ladies and Gentlemen: We have read the statements of Zivo Bioscience, Inc. pertaining to our Firm included under Item 4.01 of Form 8-K dated December 8, 2021 and agree with such statements as they pertain to our Firm. We have no basis to agree or disagree with othe
November 15, 2021	EX-10.3	Zivo Bioscience, Inc. Non-Employee Director Compensation Policy (previously filed as Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021) EXHIBIT 10.3 ZIVO BIOSCIENCE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Zivo Bioscience, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy for such Eligi
November 15, 2021	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30415 Zivo Bio
November 15, 2021	EX-10.2	Stock Option Grant Notice and Agreement to Zivo Bioscience, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 filed with the Securities and Exchange Commission on November 15, 2021) EXHIBIT 10.2 ZIVO BIOSCIENCE, INC. STOCK OPTION GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Zivo Bioscience, Inc., a Nevada corporation (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as
October 14, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 12, 2021	EX-99.1	Annual Meeting Presentation EXHIBIT 99.1
October 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission Fi
September 22, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini
September 21, 2021	EX-17.1	Letter of Resignation EXHIBIT 17.1 RESIGNATION The undersigned hereby resigns as a Director of ZIVO BIOSCIENCE, INC., a Nevada corporation (the ?Corporation?) effective on the date set forth below. This resignation is not the result of any disagreement between the undersigned and the Corporation on any matter relating to the Corporation?s operations, policies or practices. Dated 9-17-2021 /s/ Robert O. Rondeau, Jr. ROB
September 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission
September 16, 2021	8-K/A	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Jurisdiction of Incorporation) (Commission
September 13, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini
September 1, 2021	CORRESP	September 1, 2021 September 1, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Gregory Herbers Re: Zivo Bioscience, Inc. Registration Statement on Form S-3 File No. 333-259082 Acceleration Request Requested Date: September 3, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Secu
August 26, 2021	EX-4.2	ZIVO BIOSCIENCE, INC. __________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF _____________ ZIVO BIOSCIENCE, INC. FORM OF COMMON STOCK WARRANT AGREEMENT Exhibit 4.2 ZIVO BIOSCIENCE, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ZIVO BIOSCIENCE, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT(this ?Agreement?), dated as of [?], between Zivo Bioscience, Inc., a Nevada corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the l
August 26, 2021	EX-4.1	EX-4.1
August 26, 2021	S-3	As filed with the Securities and Exchange Commission on August 26, 2021 S-3 1 zivos3.htm FORM S-3 As filed with the Securities and Exchange Commission on August 26, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Zivo Bioscience, Inc. (Exact name of registrant as specified in its charter) Nevada 87-0699977 (State or other jurisdiction of incorporation or
August 16, 2021	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30415 Zivo Bioscien
June 2, 2021	EX-3.1	Certificate of Amendment effective May 28, 2021 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on June 2, 2021) Exhibit 3.1 Certificate of Amendment filed with the Secretary of State of the State of Nevada
June 2, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events 8-K 1 f8k0602218k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Juri
June 2, 2021	EX-4.1	Form of Representative’s Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 2, 2021) Representative?s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS PURCHASE WARRANT OR THE UNDERLYING SECURITIES FOR A PERIOD OF ONE HUNDRED
June 2, 2021	EX-4.3	Form of Common Stock Purchase Warrant by and between the Registrant and Direct Transfer LLC (incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on June 2, 2021) EX-4.3 6 f8k060221ex4z3.htm EXHIBIT 4.3 WARRANT AGENCY AGREEMENT, DATED JUNE 2, 2021, BY AND BETWEEN THE COMPANY AND DIRECT TRANSFER LLC WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of June 2, 2021 (the “Issuance Date”) between ZIVO Bioscience, Inc., a company incorporated under the laws of the State of Nevada (the “Company”), and Direct Transfer LLC, a Delaw
June 2, 2021	EX-99.2	1 Zivo Bioscience, Inc. Announces Closing of Upsized $13.8 Million Public Offering and Uplisting to Nasdaq JUN 02, 2021 KEEGO HARBOR, Mich., June 02, 2021 (GLOBE NEWSWIRE) - Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (?ZIVO? and the ?Company?), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derive
June 2, 2021	EX-4.2	Form of Common Stock Purchase Warrant by and between the Registrant and Direct Transfer LLC (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on June 2, 2021) COMMON STOCK PURCHASE WARRANT ZIVO BIOSCIENCE, INC. Warrant Shares: 3,174,000 Original Issuance Date: June 2, 2021 THIS COMMON STOCK PURCHASE WARRANT (this ?Warrant?) certifies that, for value received, CEDE & CO. or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th
June 2, 2021	EX-1.1	Underwriting Agreement, dated May 27, 2021, by and between the Company and Maxim Group LLC, as representative of the underwriters (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 2, 2021) EX-1.1 2 f8k060221ex1z1.htm EXHIBIT 1.1 UNDERWRITING AGREEMENT, DATED MAY 27, 2021, BY AND BETWEEN THE COMPANY AND MAXIM GROUP LLC, AS REPRESENTATIVE OF THE UNDERWRITERS EXECUTION VERSION 2,760,000 UNITS EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK ZIVO BIOSCIENCE, INC. UNDERWRITING AGREEMENT May 27, 2021 Maxim Group LLC Investment Banking
June 2, 2021	EX-99.1	1 Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq MAY 27, 2021 KEEGO HARBOR, Mich., May 27, 2021 (GLOBE NEWSWIRE) - Zivo Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, today announc
June 1, 2021	424B4	Zivo Bioscience, Inc. 2,760,000 Units Each Unit Consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock Filed pursuant to Rule 424(b)(4) Registration No. 333-251221 and 333-256580 PROSPECTUS Zivo Bioscience, Inc. 2,760,000 Units Each Unit Consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock We are offering (this “Offering”) 2,760,000 units (the “Units” and each a “Unit”), with each Unit consisting of one share of common stock, $0.001 par value per share (the
May 27, 2021	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Zivo Bioscience, Inc. (Exact name of registrant 8-A12B 1 form8a0526218a12b.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Zivo Bioscience, Inc. (Exact name of registrant as specified in its charter) Nevada 87-0699977 (State of incorporation or organization) (I.R.S. Employer Identificatio
May 27, 2021	S-1MEF	As filed with the Securities and Exchange Commission on May 27, 2021 As filed with the Securities and Exchange Commission on May 27, 2021 Registration No.
May 26, 2021	EX-10.45	Form of Paulson Convertible Note (previously filed as Exhibit 10.45 to the Registrant’s Registration Statement on Form S-1/A filed on May 26, 2021) FORM OF SENIOR SECURED CONVERTIBLE PROMISSORY NOTE $[ ]September 30, 2016 FOR VALUE RECEIVED, Zivo Bioscience, Inc.
May 26, 2021	EX-21.1	Subsidiaries of the Registrant EX-21.1 8 s1a3052421ex21z1.htm EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 Subsidiaries of the Registrant ZIVO Bioscience, Inc. has the following Subsidiaries: Jurisdiction of Incorporation or Organization Health Enhancement Corporation Nevada Corporation HEPI Pharmaceuticals, Inc. Nevada Corporation Wellmetrix, LLC Delaware limited liability company Wellmetris, LLC Delaware limited l
May 26, 2021	EX-1.1	[_____] UNITS EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK ZIVO BIOSCIENCE, INC. UNDERWRITING AGREEMENT Exhibit 1.1 [] UNITS EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK ZIVO BIOSCIENCE, INC. UNDERWRITING AGREEMENT [], 2021 Maxim Group LLC Investment Banking 405 Lexington Avenue, 2nd Fl. New York, New York 10174 As Representative of the Several Underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, ZIVO BIOSC
May 26, 2021	CORRESP	May 26, 2021 CORRESP 1 filename1.htm May 26, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Asia Timmons-Pierce Re:Zivo Bioscience, Inc. Registration Statement on Form S-1 File No. 333-251221 Acceleration Request Requested Date:May 27, 2021 Requested Time:4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461
May 26, 2021	CORRESP	Maxim Group LLC 405 Lexington Avenue New York, New York 10174 May 26, 2021 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 May 26, 2021 VIA EDGAR U.
May 26, 2021	S-1/A	As filed with the Securities and Exchange Commission on May 26, 2021 As filed with the Securities and Exchange Commission on May 26, 2021 Registration No.
May 26, 2021	EX-4.1	Warrant Agency Agreement (incorporated by reference to Exhibit 4.3 to the Registrant's Registration Statement on Form S-1/A filed on May 26, 2021) Exhibit 4.1 Form of Representative?s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS PURCHASE WARRANT OR THE UNDERLYING SECURITIES FOR A PE
May 26, 2021	EX-10.46	Form of Shapiro Convertible Note (previously filed as Exhibit 10.46 to the Registrant’s Registration Statement on Form S-1/A filed on May 26, 2021) THE NOTE EVIDENCED HEREBY HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, TILE SALE OR DISTRIBUTION THEREOF.
May 19, 2021	EX-10.44	FORM OF DEBT EXTENSION AND CONVERSION AGREEMENT EX-10.44 2 s1a2051721ex10z44.htm EXHIBIT 10.44 FORM OF DEBT CONVERSION AGREEMENT FORM OF DEBT EXTENSION AND CONVERSION AGREEMENT THIS DEBT CONVERSION AGREEMENT (this “Agreement”) is dated as of , 2021 by and between [ ] (the “Lender”), and Zivo Bioscience, Inc., a Nevada corporation (the “Company”). BACKGROUND A.Pusuant to [ ] (the “Note”), the Company is indebted to the Lender in the amount of $[
May 19, 2021	S-1/A	As filed with the Securities and Exchange Commission on May 19, 2021 As filed with the Securities and Exchange Commission on May 19, 2021 Registration No.
May 17, 2021	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30415 Zivo Bio
April 30, 2021	10-K/A	Annual Report - FORM 10-K/A AMENDED ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A (Amendment No.
April 13, 2021	S-1/A	- S-1/A AMENDED REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on April 13, 2021 Registration No.
March 17, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8k0317218k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other Ju
March 17, 2021	EX-99.1	EX-99.1 EX-99.1 2 f8k031721ex99z1.htm EXHIBIT 99.1 COMPANY PRESENTATION, DATED MARCH 17, 2021
February 25, 2021	10-K	Annual Report - FORM 10-K ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30415 Zivo Bioscience, Inc.
February 12, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 f8k02081218k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 ZIVO BIOSCIENCE, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 000-30415 87-0699977 (State or Other
January 7, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
January 7, 2021	EX-10.2	TRANSITION AND RELEASE AGREEMENT Exhibit 10.2 Transition and Release Agreement between Philip Rice and ZIVO Bioscience, Inc., dated January 7, 2021 TRANSITION AND RELEASE AGREEMENT THIS TRANSITION AND RELEASE AGREEMENT (the “Release”) is made as of the 7th day of January, 2021 by and between ZIVO Bioscience Inc. (the “Company”), and Philip M. Rice II (the “Employee”) (in the aggregate, the “Parties”). WHEREAS, the Company and Emp
January 7, 2021	EX-99.1	ZIVO BIOSCIENCE NAMES KEITH R. MARCHIANDO AS CHIEF FINANCIAL OFFICER Exhibit 99.1 Press Release, issued January 7, 2021 ZIVO BIOSCIENCE NAMES KEITH R. MARCHIANDO AS CHIEF FINANCIAL OFFICER KEEGO HARBOR, Mich., (January 7, 2021) – ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, food and feed additive products announced today that Keith R. Marchiando joined the Company’s as Chief Finan
January 7, 2021	EX-10.1	Letter Agreement between Keith Marchiando and Zivo Bioscience, Inc., dated January 1, 2021 (previously filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on January 7, 2021) EX-10.1 2 f8k010121ex10z1.htm EXHIBIT 10.1 LETTER AGREEMENT BETWEEN KEITH MARCHIANDO AND ZIVO BIOSCIENCE, INC., DATED JANUARY 1, 2021 January 1, 2021 Mr. Keith R. Marchiando 3996 Lincoln Road Bloomfield Hills, MI 48301 Re: Letter Agreement of Employment for Keith R. Marchiando (“Employee”) Dear Mr. Marchiando: The purpose of this letter is to formalize the terms and conditions of your employment,
December 9, 2020	EX-10.41	FIRST AMENDED AND RESTATED PARTICIPATION AGREEMENT Exhibit 10.41 Amended and Restated Participation Agreement FIRST AMENDED AND RESTATED PARTICIPATION AGREEMENT Strome Mezzanine Fund LP ("Strome Mezz"), Strome Alpha Fund LP ("Strome Alpha" and, together with Strome Mezz, "Participant") and HEP Investments, LLC, a Michigan limited liability company (in its capacity as a first lien lender "Lender" and, with the Participant, each a "Party" and collec
December 9, 2020	EX-4.3	Warrant Agency Agreement (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-1/A filed on May 26, 2021) EX-4.3 5 s1112120ex4z3.htm EXHIBIT 4.3 FORM OF WARRANT AGENCY AGREEMENT Exhibit 4.3 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of [], 2020 (the “Issuance Date”) between ZIVO Bioscience, Inc., a company incorporated under the laws of the State of Nevada (the “Company”), and Direct Transfer LLC, a Delaware limited liability company (the “Warrant Agent”). WHER
December 9, 2020	EX-10.38	Supply Chain Agreement with Aegle Partners 2 LLC, dated February 27, 2019 (previously filed as Exhibit 10.38 to the Registrant’s Registration Statement on Form S-1/A filed on May 26, 2021) EX-10.38 6 s1112120ex10z38.htm EXHIBIT 10.38 SUPPLY CHAIN AGREEMENT SUPPLY CHAIN CONSULTING AGREEMENT THIS SUPPLY CHAIN CONSULTING AGREEMENT (the "Agreement") is made and entered into as of February 27, 2019 (the “Effective Date”) by and between ZIVO BIOSCIENCE, INC., a Nevada corporation (the “Company”), and AEGLE PARTNERS 2 LLC, a Michigan limited liability company ("Consultant"). RECITALS A.The
December 9, 2020	EX-4.1	Form of Representative’s Warrant Agreement EX-4.1 3 s1112120ex4z1.htm EXHIBIT 4.1 FORM OF REPRESENTATIVE'S WARRANT Exhibit 4.1 Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DI
December 9, 2020	S-1	As filed with the Securities and Exchange Commission on December 9, 2020 FOrm S-1 Registration Statement As filed with the Securities and Exchange Commission on December 9, 2020 Registration No.
December 9, 2020	EX-10.40	Second Amendment to Supply Chain Agreement with Aegle Partners 2 LLC, dated November 24, 2020 (previously filed as Exhibit 10.40 to the Registrant’s Registration Statement on Form S-1/A filed on May 26, 2021) EX-10.40 8 s1112120ex10z40.htm EXHIBIT 10.40 SECOND AMENDMENT- SUPPLY CHAIN AGREEMENT SECOND AMENDMENT TO SUPPLY CHAIN CONSULTING AGREEMENT This Second Amendment to Supply Chain Consulting Agreement ("Amendment") is made as of November 24, 2020 by and between ZIVO BIOSCIENCE, INC., a Nevada corporation (the “Company”), and AEGLE PARTNERS 2 LLC, a Michigan limited liability company (“Consultant”).
December 9, 2020	EX-1.1	[_____] UNITS EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK ZIVO BIOSCIENCE, INC. UNDERWRITING AGREEMENT Exhibit 1.1 Underwriting Agreement Exhibit 1.1 [] UNITS EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK ZIVO BIOSCIENCE, INC. UNDERWRITING AGREEMENT [], 2020 Maxim Group LLC Investment Banking 405 Lexington Avenue, 2nd Fl. New York, New York 10174 As Representative of the Several Underwriters, if any, named in Schedule I hereto Ladies and Gen
December 9, 2020	EX-10.39	First Amendment to Supply Chain Agreement with Aegle Partners 2 LLC, dated September 14, 2019 (previously filed as Exhibit 10.39 to the Registrant’s Registration Statement on Form S-1/A filed on May 26, 2021) EX-10.39 7 s1112120ex10z39.htm EXHIBIT 10.39 FIRST AMENDMENT TO SUPPLY CHAIN AGREEMENT FIRST AMENDMENT TO SUPPLY CHAIN CONSULTING AGREEMENT This First Amendment to Supply Chain Consulting Agreement ("Amendment") is made as of September 14, 2019 by and between ZIVO BIOSCIENCE, INC., a Nevada corporation (the “Company”), and AEGLE PARTNERS 2 LLC, a Michigan limited liability company (“Consultant”).
December 9, 2020	EX-4.2	COMMON STOCK PURCHASE WARRANT ZIVO BIOSCIENCE, INC. Warrant Shares: [_______] Original Issuance Date: [____], 2020 Exhibit 4.2 Form of Common Stock Purchase Warrant Exhibit 4.2 COMMON STOCK PURCHASE WARRANT ZIVO BIOSCIENCE, INC. Warrant Shares: [] Original Issuance Date: [], 2020 THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at
December 9, 2020	EX-21.1	Subsidiaries of the Registrant EX-21.1 10 s1112120ex21z1.htm EXHIBIT 21.1 SUBSIDIARIES Exhibit 21.1 Subsidiaries of the Registrant ZIVO Bioscience, Inc. has the following Subsidiaries: Jurisdiction of Incorporation or Organization Health Enhancement Corporation Nevada Corporation HEPI Pharmaceuticals, Inc. Nevada Corporation Wellmetrix, LLC (fka WellMetris, LLC) Delaware limited liability company Zivo Biologic, Inc. Delaware co
November 17, 2020	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 f8k1111208k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 ZIVO BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-30415 87-0699977 (State or other j
November 12, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 ZIVO BIOSCIENCE, INC.
November 12, 2020	EX-99.1	1 Exhibit 99.1 President’s Report to Shareholders dated November 11, 2020. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 4 Good morning. Welcome to our virtual attendees and those on the call-in line. And, welcome to our board of directors, company principals and consultants online today. My name is Andrew Dahl, president and chief executive officer of ZIVO Bioscience Incorporated, a f
November 12, 2020	EX-10.1	LICENSE CO-DEVELOPMENT PARTICIPATION AGREEMENT Exhibit 10.1 LICENSE CO-DEVELOPMENT PARTICIPATION AGREEMENT THIS LICENSE CO-DEVELOPMENT PARTICIPATION AGREEMENT (this "Agreement") is made and entered into as of [], 2020 (the “Effective Date”) by and between ZIVO BIOSCIENCE, INC., a Nevada corporation (“ZIVO” or the “Company”), whose address is 2804 Orchard Lake Rd., Suite 202, Keego Harbor, Michigan 48320, Attention: Andrew Dahl, CEO, whose emai
November 12, 2020	10-Q	United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q Form 10Q Quarterly Report United States Securities and Exchange Commission Washington, D.
October 19, 2020	DEFR14A	- DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
October 13, 2020	EX-9	License Co-Development Participation Agreement dated October 8, 2020, by and between Zivo Bioscience, Inc. and Strome Mezzanine Fund, LP incorporated by reference from Exhibit 9 to Strome Mezzanine’s Schedule 13D/A filed with the SEC on October 13, 2020. EX-9 2 e11405ex9.htm LICENSE CO-DEVELOPMENT PARTICIPATION AGREEMENT LICENSE CO-DEVELOPMENT PARTICIPATION AGREEMENT THIS LICENSE CO-DEVELOPMENT PARTICIPATION AGREEMENT (this "Agreement") is made and entered into as of October 8, 2020 (the “Effective Date”) by and between ZIVO Bioscience, Inc., a Nevada corporation (“ZIVO” or the “Company”), whose address is 2804 Orchard Lake Rd., Suite 202, Keego H
October 13, 2020	SC 13D/A	ZIVO / Zivo Bioscience, Inc. / STROME MEZZANINE FUND, LP - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Timothy R. Damschroder Bodman PLC 201 S. Division, Suite 400 Ann Arbor, MI 48104 (Name, Address and Telephone Number of Person
October 8, 2020	PRER14A	- PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement – Revised ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)
August 13, 2020	10-Q	Quarterly Report - FORM 10Q QUARTERLY REPORT Form 10Q Quarterly Report United States Securities and Exchange Commission Washington, D.
May 11, 2020	10-Q	Quarterly Report - FORM 10 Q QUARTERLY REPORT 10-Q 1 f10q03312010q.htm FORM 10 Q QUARTERLY REPORT United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio
April 29, 2020	DEF 14A	- DEFINITIVE 14A PROXY STATEMENT Definitive 14A Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 26, 2020	EX-10.34	2019 Omnibus Long-Term Incentive Plan (previously filed as Exhibit 10.34 to the Registrant’s Annual Report on Form 10-K filed on March 26, 2020) Exhibit 10.34 2019 Omnibus Long-Term Incentive Plan Exhibit 10.34 ZIVO BIOSCIENCE, INC. 2019 OMNIBUS LONG-TERM INCENTIVE PLAN ZIVO Bioscience, Inc., a Nevada corporation (the “Company”), sets forth herein the terms of its 2019 Omnibus Long-Term Incentive Plan (the “Plan”), as follows: Section 1 PURPOSE The Plan is intended to enhance the ability of the Company and the Subsidiaries and Affiliates t
March 26, 2020	EX-10.36	ZIVO BIOSCIENCE, INC. STOCK OPTION GRANT NOTICE (2019 OMNIBUS LONG-TERM INCENTIVE PLAN) Exhibit 10.36 Stock Option Grant Notice for 2019 Omnibus Long-Term Incentive Plan - A. Dahl Exhibit 10.36 ZIVO BIOSCIENCE, INC. STOCK OPTION GRANT NOTICE (2019 OMNIBUS LONG-TERM INCENTIVE PLAN) Zivo Bioscience, Inc. (the “Company”), pursuant to its 2019 Omnibus Long-Term Incentive Plan (the “Plan”) hereby grants to Participant an option to purchase the number of Shares of the Company’s common stoc
March 26, 2020	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant ZIVO Bioscience, Inc. has the following Subsidiaries: Jurisdiction of Incorporation or Organization Health Enhancement Corporation Nevada Corporation HEPI Pharmaceuticals, Inc. Nevada Corporation Wellmetrix, LLC (fka WellMetris, LLC) Delaware limited liability corporation Zivo Biologic, Inc. Delaware corporation
March 26, 2020	EX-4.1	DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 4.1 Description of Securities Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following is a brief description of shares of common stock (“common stock”) of ZIVO Bioscience, Inc. (the “Company,” “we,” “us,” or “our”). The brief description is based upon our Articles of Incorporation, including the Certificate of Amendment to our Articles of Incorpo
March 26, 2020	EX-14.1	ZIVO BIOSCIENCE EMPLOYEE ETHICS POLICIES Code of Ethics and Business Conduct for Officers, Directors and Employees Exhibit 14.1 Code of Ethics Exhibit 14.1 ZIVO BIOSCIENCE EMPLOYEE ETHICS POLICIES Code of Ethics and Business Conduct for Officers, Directors and Employees 1. Treat in an Ethical Manner Those to Whom Zivo Bioscience Has an Obligation We are committed to honesty, just management, fairness, providing a safe and healthy environment free from the fear of retribution, and respecting the dignity due eve
March 26, 2020	10-K	HEPI / 10-K - Annual Report - 10K ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30415 Zivo Bioscience, Inc.
March 26, 2020	EX-10.33	AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.33 Amended and Restated Employment Agreement with Andrew Dahl, dated as of November 29, 2019 Exhibit 10.33 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of November 15, 2019 (the “Effective Date”), by and between ZIVO Bioscience Inc., a Nevada corporation (the “Company”), and Andrew A. Dahl (“Employ
March 26, 2020	EX-10.35	13 Form of Release EMPLOYMENT AGREEMENT RELEASE Exhibit 10.35 Philip M. Rice Employment Letter, dated as of March 4, 2020 Exhibit 10.35 March 4, 2020 Mr. Philip M. Rice II 13437 Redmonds Hill Ct. Chelsea, MI 48118 Re: Letter Agreement of Employment for Philip M. Rice II (“Employee”) Dear Mr. Rice: The purpose of this letter is to formalize the terms and conditions of your employment, and your employment relationship, with ZIVO Bioscience Inc.,
March 26, 2020	EX-10.37	Stock Option Grant Notice for 2019 Omnibus Long-Term Incentive Plan (previously filed as Exhibit 10.37 to the Registrant’s Annual Report on Form 10-K filed on March 26, 2020) Exhibit 10.37 Stock Option Grant Notice for 2019 Omnibus Long-Term Incentive Plan - A. Dahl Exhibit 10.37 ZIVO BIOSCIENCE, INC. STOCK OPTION GRANT NOTICE (2019 OMNIBUS LONG-TERM INCENTIVE PLAN) Zivo Bioscience, Inc. (the “Company”), pursuant to its 2019 Omnibus Long-Term Incentive Plan (the “Plan”) hereby grants to Participant an option to purchase the number of Shares of the Company’s common stoc
March 10, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 ZIVO BIOSCIENCE, INC.
March 9, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 ZIVO BIOSCIENCE, INC.
March 5, 2020	SC 13D/A	HEPI / / YALDOO LAITH L - SCHEDULE 13D/A3 Activist Investment Schedule 13D/A3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Laith Yaldoo c/o HEP Investments LLC 2804 Orchard Lake Rd., Suite 205, Keego Harbor, MI 48302 (Name, Address an
March 5, 2020	SC 13D/A	HEPI / / HEP INVESTMENTS LLC - SCHEDULE 13D/A3 Activist Investment Schedule 13D/A3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Laith Yaldoo c/o HEP Investments LLC 2804 Orchard Lake Rd., Suite 205, Keego Harbor, MI 48302 (Name, Address an
February 25, 2020	SC 13D/A	HEPI / / Strome Mezzanine Fund, Lp - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Timothy R. Damschroder Bodman PLC 201 S. Division, Suite 400 Ann Arbor, MI 48104 (Name, Address and Telephone Number of Person
February 19, 2020	SC 13D	ZIVO / Zivo Bioscience, Inc. / Maggiore Christopher D. - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Christopher D. Maggiore 4788 Nobles Pond Dr. NW, Canton, OH 44718 (Name, Address and Telephone Number of Person Au
December 5, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 f8k1210198k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2019 ZIVO BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-30415 87-0699977 (State or other j
October 28, 2019	10-Q	ZIVO / Zivo Bioscience, Inc. 10-Q - Quarterly Report - FORM 10Q QUARTERLY REPORT Form 10Q Quarterly Report U.S. Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30415
August 7, 2019	10-Q	ZIVO / Zivo Bioscience, Inc. 10-Q - Quarterly Report - FORM 10Q QUARTERLY REPORT Form 10Q Quarterly Report U.S. Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30415 Zivo
May 13, 2019	10-Q	ZIVO / Zivo Bioscience, Inc. 10-Q Quarterly Report FORM 10 Q QUARTERLY REPORT Form 10 Q Quarterly Report U.S. Securities and Exchange Commission Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-30415 Zi
May 7, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K 1 f8k0507198k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 ZIVO BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-30415 87-0699977 (State or other jurisdi
May 7, 2019	EX-3.1	EX-3.1 Articles of Amendment, as filed with the Secretary of State of the State of Nevada on May 2, 2019.
May 1, 2019	8-K	Financial Statements and Exhibits, Other Events Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 ZIVO BIOSCIENCE, INC.
May 1, 2019	EX-99.1	Exhibit 99.1 Exhibit 99.1 President’s Report to Shareholders dated May 1, 2019.
April 29, 2019	DEFA14A	ZIVO / Zivo Bioscience, Inc. DEFA14A DEFINITIVE PROXY ADDITIONAL MATERIALS DEFA14A 1 defa14a042919defa14a.htm DEFINITIVE PROXY ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confide
April 8, 2019	EX-10.2	DEBT CONVERSION AGREEMENT EX-10.2 3 f8k040819ex10z2.htm EXHIBIT 10.2 DEBT CONVERSION AGREEMENT WITH HEP INVESTMENTS, LLC DATED APRIL 5, 2019. Exhibit 10.2 DEBT CONVERSION AGREEMENT THIS DEBT CONVERSION AGREEMENT (this “Agreement”) is dated as of April 5, 2019 by and between HEP Investments LLC, a Michigan limited liability company (the “Lender”), and Zivo Bioscience, Inc., a Nevada corporation (the “Company”). BACKGROUND A
April 8, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2019 ZIVO BIOSCIENCE, INC.
April 8, 2019	EX-10.1	DEBT EXTENSION AGREEMENT EX-10.1 2 f8k040819ex10z1.htm DEBT EXTENSION AGREEMENT WITH HEP INVESTMENTS, LLC DATED MARCH 29, 2019 Exhibit 10.1 DEBT EXTENSION AGREEMENT THIS DEBT EXTENSION AGREEMENT (this “Agreement”) is dated as of March 29, 2019 by and between HEP Investments LLC, a Michigan limited liability company (the “Lender”), and Zivo Bioscience, Inc., a Nevada corporation (the “Company”). BACKGROUND A.Pursuant to a
March 25, 2019	DEFR14A	ZIVO / Zivo Bioscience, Inc. REVISED DEFINITIVE 14A PROXY STATEMENT DEFR14A 1 defr14a032519defr14a.htm REVISED DEFINITIVE 14A PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) [X] Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidenti
March 19, 2019	DEF 14A	ZIVO / Zivo Bioscience, Inc. DEFINITIVE 14A PROXY STATEMENT DEF 14A 1 def14a031819def14a.htm DEFINITIVE 14A PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) [X] Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Us
February 28, 2019	PRE 14A	ZIVO / Zivo Bioscience, Inc. PRELIMINARY PROXY Preliminary Proxy UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by
February 27, 2019	SC 13D/A	ZIVO / Zivo Bioscience, Inc. / HEP INVESTMENTS LLC - SCHEDULE 13D/A4 Activist Investment Schedule 13D/A4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Laith Yaldoo c/o HEP Investments LLC 2804 Orchard Lake Rd., Suite 205, Keego Harbor, MI 48302 (Name, Address an
February 27, 2019	SC 13D/A	ZIVO / Zivo Bioscience, Inc. / Maggiore Christopher D. - SCHEDULE 13D/A Activist Investment Schedule 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Christopher D. Maggiore 4788 Nobles Pond Dr. NW, Canton, OH 44718 (Name, Address and Telephone Number of Person
February 27, 2019	SC 13D/A	ZIVO / Zivo Bioscience, Inc. / YALDOO LAITH L - SCHEDULE 13D/A4 Activist Investment Schedule 13D/A4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Zivo Bioscience, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 98978N 101 (CUSIP Number) Laith Yaldoo c/o HEP Investments LLC 2804 Orchard Lake Rd., Suite 205, Keego Harbor, MI 48302 (Name, Address an

ZIVO / ZIVO Bioscience, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings